Two Sigma Investments LP Sells 68,646 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Two Sigma Investments LP lessened its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 7.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 839,270 shares of the biotechnology company’s stock after selling 68,646 shares during the quarter. Two Sigma Investments LP owned about 1.17% of Aclaris Therapeutics worth $2,081,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Peapod Lane Capital LLC acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter worth about $1,003,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter worth about $82,000. Raymond James Financial Inc. acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter worth about $383,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Aclaris Therapeutics by 173.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 908,819 shares of the biotechnology company’s stock valued at $2,254,000 after buying an additional 576,413 shares during the last quarter. Finally, Commonwealth Equity Services LLC purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at about $36,000. Institutional investors own 98.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ACRS shares. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective (down previously from $20.00) on shares of Aclaris Therapeutics in a research note on Wednesday, May 14th. Wedbush started coverage on shares of Aclaris Therapeutics in a research note on Wednesday, May 28th. They issued an “outperform” rating and a $8.00 price objective for the company. Wall Street Zen lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Finally, Scotiabank reduced their target price on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating for the company in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Aclaris Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $9.71.

Aclaris Therapeutics Trading Down 0.7%

ACRS opened at $1.45 on Monday. The company has a 50 day moving average of $1.30 and a 200 day moving average of $2.16. The company has a market cap of $157.01 million, a PE ratio of -2.79 and a beta of 0.42. Aclaris Therapeutics, Inc. has a 12 month low of $0.99 and a 12 month high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. Research analysts forecast that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current fiscal year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.